Does Relmada Therapeutics (RLMD) Have the Potential to Rally 75.58% as Wall Street Analysts Expect?

The mean of analysts' price targets for Relmada Therapeutics (RLMD) points to a 75.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.